Preliminary experiments have shown that GranaGard can reduce the activity of Complex I in the respiratory chain of the mitochondria. While this can somewhat reduce the production of ATP, it can concomitantly inhibit the formation of free radicals, thereby reducing the toxicity of respiration to cells.
Granalix is conducting a survey among peolpe taking GranaGard for several months. No adverse effect have been reported. Among the benefits most described were: Increased alertness and fitness for physical activity.
Granalix is planning a clinical trial for CJD patients and carriers of CJD related mutations.
Granalix is planning a clinical trial for early AD patients.